2024-10-19 - Analysis Report
## AMGN Stock Analysis Report 

**Company Overview:** Amgen Inc. is a leading biotechnology company that develops, manufactures, and markets a wide range of medicines for serious illnesses. 

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return:** AMGN: 79.88%, VOO (S&P 500): 137.88%. 
* **Relative Performance:** AMGN has underperformed the S&P 500 by -58.0%. This places AMGN at the 28.12 percentile of its historical performance range.

**2. Recent Price Movement:**

* **Closing Price:** $321.66
* **5-day Moving Average:** $322.87
* **20-day Moving Average:** $322.45
* **60-day Moving Average:** $326.54 
* **Analysis:** The stock is trading slightly below its 5-day and 20-day moving averages, suggesting potential short-term downward pressure. However, it remains above the 60-day moving average, indicating longer-term support. 

**3. Technical Indicators:**

* **RSI:** 49.12 (Neutral) - Indicates that the stock is neither overbought nor oversold.
* **PPO:** 0.06 (Positive) - Suggests a slight upward momentum.
* **Delta_Previous_Relative_Divergence:** -14.19 (Short-term Downward Trend) - Suggests a recent decline in relative strength.
* **Expected Return:** 0.0% (Long-term) - Indicates potential for modest growth, but not significantly outperforming the S&P 500 over the next 2+ years.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-07 | 1.39 | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23 | 6.90 B$ |
| 2023-08-04 | 2.58 | 6.99 B$ |
| 2024-08-07 | 2.58 | 6.99 B$ |

**Analysis:** The most recent earnings report (2024-08-07) showed an EPS of 1.39, exceeding analyst estimates. Revenue also came in strong at 8.39B$, indicating solid performance. 

**5. Recent News and Issues:**

* **Market Outlook:**  Recent news suggests a mixed outlook for AMGN. While its recent earnings beat and strong revenue demonstrate continued growth, concerns remain about its reliance on existing products and potential competition in the biopharmaceutical space.
* **Analyst Opinions:** Analyst sentiment varies, with some expecting continued growth driven by product innovation and market expansion. However, others highlight the need for AMGN to diversify its product portfolio and mitigate the impact of potential patent expirations. 
* **Performance Highlights:** AMGN's recent performance has been driven by successful launches of key products, including its treatment for a rare genetic disease.

**Overall Analysis:**

AMGN is a mature company with a strong market presence, facing competition and a need to diversify its product portfolio. Despite recent positive earnings, long-term outperformance compared to the S&P 500 is not expected. Technical indicators suggest neutral momentum, with recent price movements hinting at possible short-term downward pressure.  Investors should closely monitor the company's efforts to introduce new products and expand into new markets to assess future potential. 
